Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Companyโs other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
์ข
๋ชฉ ์ฝ๋ MCRB
ํ์ฌ ์ด๋ฆSeres Therapeutics Inc
์์ฅ์ผJun 26, 2015
CEOThorell (Marella)
์ง์ ์103
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJun 26
์ฃผ์101 Cambridge Park Drive
๋์CAMBRIDGE
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02140
์ ํ16179459626
์น์ฌ์ดํธhttps://www.serestherapeutics.com/
์ข
๋ชฉ ์ฝ๋ MCRB
์์ฅ์ผJun 26, 2015
CEOThorell (Marella)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์